Ethinyl Estradiol Interactions

Bosentan decreases ethinyl estradiol exposure by average of 31%, with decreases up to 66% in individual subjects, reducing hormonal contraceptive effectiveness.

Source: NLP:bosentan

PYRUKYND induces CYP3A, decreasing systemic concentrations of this hormonal contraceptive. Monitor for loss of contraceptive efficacy or use non-hormonal alternatives.

Source: NLP:mitapivat

Levels may be increased when co-administered with atorvastatin.

Source: NLP:amlodipine besylate and atorvastatin calcium

Effectiveness of steroidal contraceptives may be reduced when used with armodafinil. Alternative or concomitant methods of contraception are recommended during treatment and for one month after discontinuation.

Source: NLP:armodafinil

Oral contraceptive component; atorvastatin may increase ethinyl estradiol values.

Source: NLP:atorvastatin calcium

WELCHOL may decrease exposure of ethinyl estradiol. Administer oral contraceptive 4 hours prior to WELCHOL.

Source: NLP:colesevelam hydrochloride

Eslicarbazepine acetate is associated with lower plasma levels of ethinylestradiol, potentially decreasing hormonal contraceptive effectiveness. Additional or alternative non-hormonal birth control is recommended.

Source: NLP:eslicarbazepine acetate

Ferric maltol may decrease bioavailability of ethinyl estradiol. Separate administration by at least 4 hours and monitor clinical response.

Source: NLP:ferric maltol

Fluconazole 200 mg increased ethinyl estradiol AUC by 38% and fluconazole 300 mg increased it by 24%. Fluconazole 50 mg showed no significant effect.

Source: NLP:fluconazole

Estrogen-containing oral contraceptive with 30 mcg ethinylestradiol decreases lamotrigine concentrations approximately 50%.

Source: NLP:lamotrigine

Estrogen-containing oral contraceptives decrease lamotrigine concentrations approximately 50%. Lamotrigine may decrease levonorgestrel component by 19%.

Source: NLP:lamotrigine er

Teriflunomide may increase systemic exposure of ethinylestradiol. Consideration should be given to type or dose of oral contraceptives used with leflunomide.

Source: NLP:leflunomide

Effectiveness of steroidal contraceptives may be reduced when used with modafinil. Alternative or concomitant contraception methods recommended during treatment and for one month after discontinuation.

Source: NLP:modafinil

Nevirapine decreases ethinyl estradiol plasma levels. Oral contraceptives should not be used as sole contraception method; alternative or additional contraception recommended.

Source: NLP:nevirapine

Oral contraceptive component that may increase roflumilast systemic exposure and result in increased side effects when co-administered.

Source: NLP:roflumilast

Estrogen that reduces oral clearance of ropinirole by 36%; starting or stopping may require dose adjustment of ropinirole.

Source: NLP:ropinirole

Teriflunomide may increase systemic exposure of ethinylestradiol. Consideration should be given to the type or dose of contraceptives used.

Source: NLP:teriflunomide

Component of oral contraceptives; CYP2C19 inhibition may increase voriconazole levels. Monitor for adverse reactions and toxicity.

Source: NLP:voriconazole

Clinical trial showed no clinically relevant changes in pharmacokinetics or hormone levels at recommended isotretinoin dosages.

Source: NLP:isotretinoin

Concomitant use of tazarotene did not affect the pharmacokinetics of ethinyl estradiol in a trial of 27 healthy female subjects receiving oral contraceptive combination.

Source: NLP:tazarotene

Zafirlukast has no significant effect on ethinyl estradiol plasma concentrations or contraceptive efficacy.

Source: NLP:zafirlukast